We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS has formally appealed a July ruling by a federal court in Washington, D.C., which blocked the department from requiring drug companies to disclose the prices of drug prices in their direct-to-consumer TV ads. Read More
The FDA is delaying enforcement action for one year against wholesale distributors who fail to comply with certain sections of the Drug Supply Chain Security Act (DSCSA), the agency said in a new guidance released on Tuesday. Read More
The agency is providing a two-year transition period for sponsors to make changes to their manufacturing processes and to implement adequate testing methods. Read More
The filing came just days after the FDA and EMA announced they are investigating the drug after learning that it contained low levels of the impurity. Read More
The FDA urges trial sponsors who may be thinking of using Bayesian statistics in complex innovative trials to consider alternatives, in a new draft guidance issued Monday. Read More
Senior FDA officials promised “flexibility” to help address the unmet medical need as the agency released final guidance on Monday for sponsors of treatments for amyotrophic lateral sclerosis (ALS) — Lou Gehrig’s disease. Read More
Americans pay on average nearly four times more for prescription drugs than citizens in comparable countries, the House Ways and Means Committee claims in a report released on Monday. Read More
The DEA is seeking public comment from legitimate industries that use the substance and the potential burden the proposed regulatory controls may have on their activities. Read More